Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT)

• DOI: 10.1111/jdv.19730
• Publication Date: 2023-12-12T23:49:25Z
• Authors: Fabio Verardi; Lara Valeska Maul; Kim Borsky; Simona Steinmann; Nina Rosset; Hector Ortega Pons; Christina Sorbe; Nikhil Yawalkar; Raphael Micheroli; Alexander Egeberg; Jacob P. Thyssen; Kristine Heidemeyer; Wolf‐Henning Boeh...; Curdin Conrad; Antonio Cozzio; Andreas Pinter; Thomas Kündig; Alexander A. Nava...; Julia‐Tatjana Maul
• Keywords: MedDRA; Discontinuation

Abstract Background Psoriasis is a disease that often requires prolonged systemic treatment. It important to determine the safety of available therapies. There currently little insight into sex‐specific differences in psoriasis Objectives To examine real‐world, long‐term therapies with sex stratification drug‐related adverse events (ADRs). Methods Ten‐year data from adults moderate‐to‐severe requiring treatment (conventional [CST], biologics) were obtained Swiss registry (SDNTT). ADRs categorized according international terminology Medical Dictionary for Regulatory Activities (MedDRA). Safety was assessed by calculating event rates per 100 patient‐years (PY). We used descriptive statistics patient and characteristics, binomial t ‐tests compare groups sex. Results In total, 791 patients (290 females) included mean age 46 years. 358 (45%) received CSTs 433 (55%) biologics; both had similar baseline characteristics except more joint involvement using biologics (26.86% vs. 14.8%, p < 0.0001). associated 2.2‐fold higher ADR rate (40.43/100 PY 18.22/100 PY, 0.0001) an 8.0‐fold discontinuation than (0.16/PY 0.02/PY, Trends showed non‐significant serious (8.19, CI 6.87–9.68) compared (7.08, 5.39–9.13) ( = 0.3922). Sex revealed significantly overall all treatments females (1.8‐fold [57.30/100 31.69/100 PY] 2.0‐fold [27.36/100 13.9/100 PY], 0.0001), most females. Conclusion Females rates. should be taken consideration when designing studies patient‐tailored management psoriasis.